Rifaximin derivative and uses thereof
25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
1. A sodium, potassium, calcium, magnesium, ammonium, or chlorine pharmaceutically acceptable salt of 25-desacetyl rifaximin, wherein the 25-desacetyl rifaximin is of the formula:
2. A pharmaceutically acceptable acid addition salt of 25-desacetyl rifaximin, wherein the 25-desacetyl rifaximin is of the formula:
3. The pharmaceutically acceptable acid addition salt of claim 2 , wherein the acid addition salt is selected from hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzensoulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, and methanesulfonate.
4. A pharmaceutically acceptable base addition salt of 25-desacetyl rifaximin, wherein the 25-desacetyl rifaximin is of the formula:
5. The pharmaceutically acceptable acid addition salt of claim 4 , wherein the base addition salt is selected from sodium, potassium, magnesium, and calcium.
6. A pharmaceutical composition comprising the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 1 ; and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 2 ; and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 4 ; and a pharmaceutically acceptable carrier.
9. A method for treating irritable bowel syndrome, travelers' diarrhea, small intestinal bacterial overgrowth, or hepatic encephalopathy, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 1 .
10. The method of claim 9 , wherein the traveler's diarrhea is caused by exposure to one or more enteric pathogens.
11. The method of claim 10 , wherein the one or more enteric pathogens is selected from Salmonella spp., Shigella spp., Campylobacter spp., Aeromonas, Plesiomonas, Vibro spp., Yersinia entercolitica, E. coli , Enterotoxigenic Escherichia coli (ETEC), E. coli 0157:H7 , C. difficile and H. pylori.
12. The method of claim 10 , wherein the enteric pathogens comprise one or more of a gram-positive bacteria, a gram-negative bacteria, an aerobic bacteria or an anaerobic bacteria.
13. A method for treating irritable bowel syndrome, travelers' diarrhea, small intestinal bacterial overgrowth, or hepatic encephalopathy, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 2 .
14. The method of claim 13 , wherein the traveler's diarrhea is caused by exposure to one or more enteric pathogens.
15. The method of claim 14 , wherein the one or more enteric pathogens is selected from Salmonella spp., Shigella spp., Campylobacter spp., Aeromonas, Plesiomonas, Vibro spp., Yersinia entercolitica, E. coli , Enterotoxigenic Escherichia coli (ETEC), E. coli 0157:H7 , C. difficile and H. pylori.
16. The method of claim 14 , wherein the enteric pathogens comprise one or more of a gram-positive bacteria, a gram-negative bacteria, an aerobic bacteria or an anaerobic bacteria.
17. A method for treating irritable bowel syndrome, travelers' diarrhea, small intestinal bacterial overgrowth, or hepatic encephalopathy, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutically acceptable salt of 25-desacetyl rifaximin according to claim 4 .
18. The method of claim 17 , wherein the traveler's diarrhea is caused by exposure to one or more enteric pathogens.
19. The method of claim 18 , wherein the one or more enteric pathogens is selected from Salmonella spp., Shigella spp., Campylobacter spp., Aeromonas, Plesiomonas, Vibro spp., Yersinia entercolitica, E. coli , Enterotoxigenic Escherichia coli (ETEC), E. coli 0157:H7 , C. difficile and H. pylori.
20. The method of claim 18 , wherein the enteric pathogens comprise one or more of a gram-positive bacteria, a gram-negative bacteria, an aerobic bacteria or an anaerobic bacteria.